市场调查报告书
商品编码
1298765
2023-2028年按疾病类型(活动性肺结核、潜伏性肺结核和其他)、诊断和治疗(诊断、治疗)、终端用户(医院、专科诊所、家庭护理和其他)和地区分類的抗结核治疗药物市场Anti-Tuberculosis Therapeutics Market by Disease Type (Active TB, Latent TB, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Specialty Clinics, Homecare, and Others), and Region 2023-2028 |
2022年,全球抗结核治疗剂的市场规模达到13.5479亿美元。展望未来,IMARC集团预计,到2028年,市场规模将达到19.9134亿美元,在2023-2028年期间表现出6.70%的增长率(CAGR)。不断增长的医疗支出、有利的报销政策、技术进步和不断增长的公私合作关系代表了推动市场发展的一些关键因素。
抗结核治疗药物是指用于管理结核病(TB)的药物和治疗策略,结核病是由结核分枝杆菌引起的细菌感染。结核病主要影响肺部,也可扩散到身体的其他部位,如肾脏、脊柱和大脑。抗结核治疗法用于从体内消灭细菌并防止感染扩散。这是通过联合使用抗生素来实现的,这些抗生素通常要开六到九个月。一些最常用的药物包括异烟肼、利福平、乙胺丁醇和吡嗪酰胺。具体使用的药物组合取决于感染的严重程度和病人的健康状况。此外,定期监测和随访对于确保治疗成功和防止耐药结核病的发生也是至关重要的。近年来,抗结核治疗剂获得了牵引力,因为它还涉及支持性护理,如氧气治疗、营养支持和可能出现的并发症管理。
推动市场发展的主要因素之一是全球结核病(TB)的高发病率,特别是在中低收入国家。此外,由于治疗不彻底、医疗基础设施不足以及缺乏适当的医疗服务,耐药性结核病的发生率越来越高,这对市场的增长产生了积极的影响。除此之外,新药和治疗策略的开发也在推动抗结核治疗剂市场的发展。近年来,一些新药,如贝达喹啉和德拉马尼,已被批准用于治疗结核病。与传统的结核病药物相比,这些药物具有更好的疗效和安全性。与此相呼应,技术和诊断的进步使结核病的早期检测和诊断成为可能,从而导致及时开始治疗和更好的病人结果,这代表了另一个主要的增长诱导因素。此外,医疗保健支出的增加,特别是在新兴经济体,已经导致医疗保健基础设施的改善,增加了获得高质量医疗保健的机会,包括结核病治疗。除此之外,人们对结核病的认识不断提高,以及早期诊断和治疗的重要性,也使抗结核病疗法的需求升级。此外,政府对结核病控制项目的倡议和资助在推动抗结核病治疗剂市场方面发挥了重要作用。例如,政府和非政府组织(NGO)正在合作,以提高意识,改善诊断,并确保获得负担得起的有效治疗,这预计将在未来几年内推动市场增长。
请注意,这只代表部分公司的名单,完整的名单已在报告中提供。
The global anti-tuberculosis therapeutics market size reached US$ 1,354.79 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,991.34 Million by 2028, exhibiting a growth rate (CAGR) of 6.70% during 2023-2028. The rising healthcare spending, favorable reimbursement policies, technological advancements, and growing public-private partnerships represent some of the key factors driving the market.
Anti-tuberculosis therapeutics refer to the drugs and treatment strategies used to manage tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. TB primarily affects the lungs and can also spread to other parts of the body, such as the kidneys, spine, and brain. Anti-tuberculosis therapeutics are used to eradicate the bacteria from the body and prevent the spread of the infection. This is achieved through a combination of antibiotics that are typically prescribed for six to nine months. Some of the most commonly used drugs include isoniazid, rifampin, ethambutol, and pyrazinamide. The exact combination of drugs used depends on the severity of the infection and the patient's health status. In addition, regular monitoring and follow-up are also essential to ensure treatment success and prevent the development of drug-resistant TB. In recent years, anti-tuberculosis therapeutics have gained traction as it also involves supportive care, such as oxygen therapy, nutrition support, and management of complications that may arise.
One of the primary factors driving the market is the high prevalence of tuberculosis (TB) worldwide, particularly in low- and middle-income countries. Additionally, the growing incidence of drug-resistant TB due to incomplete treatment, inadequate healthcare infrastructure, and lack of access to appropriate healthcare is positively influencing the market growth. Other than this, the development of new drugs and treatment strategies is also driving the anti-tuberculosis therapeutics market. In recent years, several new drugs, such as bedaquiline and delamanid, have been approved for the treatment of TB. These drugs offer improved efficacy and safety profiles compared to traditional TB drugs. In line with this, advancements in technology and diagnostics have enabled early detection and diagnosis of TB, leading to timely initiation of treatment and better patient outcomes, which represents another major growth-inducing factor. Furthermore, the increase in healthcare spending, particularly in emerging economies, has led to improved healthcare infrastructure and increased access to quality healthcare, including TB treatment. Apart from this, the growing awareness about TB and the importance of early diagnosis and treatment has also escalated the demand for anti-tuberculosis therapeutics. Moreover, government initiatives and funding for TB control programs have played a significant role in driving the anti-tuberculosis therapeutics market. For instance, governments and non-governmental organizations (NGOs) are working together to increase awareness, improve diagnosis, and ensure access to affordable and effective treatments, which is expected to drive market growth in the upcoming years.
IMARC Group provides an analysis of the key trends in each segment of the global anti-tuberculosis therapeutics market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on the disease type, diagnosis and treatment, and end user.
Active TB
Latent TB
Others
The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the disease type. This includes active TB, latent TB, and others.
Diagnosis
Blood Tests
Imaging Tests
Sputum Tests
Others
Treatment
First-Line of Drugs
Isoniazid
Ethambutol
Rifampin
Others
Second-Line of Drugs
Thiacetazone
Paraaminosalicyclic Acid (PAS)
Others
Others
A detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the diagnosis and treatment has also been provided in the report. This includes diagnosis (blood tests, imaging tests, sputum tests, and others), treatment (first-line of drugs (isoniazid, ethambutol, rifampin, and others) second-line of drugs (thiacetazone, paraaminosalicyclic acid (PAS), and others), and others
Hospitals
Specialty Clinics
Homecare
Others
The report has provided a detailed breakup and analysis of the anti-tuberculosis therapeutics market based on the end user. This includes hospitals, specialty clinics, homecare, and others.
North America
United States
Canada
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for anti-tuberculosis therapeutics. Some of the factors driving the North America anti-tuberculosis therapeutics market included rising prevalence of tuberculosis, growing drug resistance, and numerous government initiatives.
The report has also provided a comprehensive analysis of the competitive landscape in the global anti-tuberculosis therapeutics market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include F Hoffmann-La Roche Ltd., Lannett Company Inc., Lupin Limited, Macleods Pharmaceuticals Limited, Otsuka Pharmaceutical Co. Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.